Detalhe da pesquisa
1.
Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post-hoc Analysis of KALM-1 and KALM-2.
Am J Nephrol
; 2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38253036
2.
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
N Engl J Med
; 382(3): 222-232, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31702883
3.
Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
Nephrol Dial Transplant
; 2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37968132
4.
Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic pain.
Geriatr Nurs
; 38(1): 39-47, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27502432
5.
Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain.
Pain Pract
; 17(3): 382-391, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27317188
6.
Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.
Pain Pract
; 16(3): 345-58, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25599968
7.
A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
Pain Pract
; 16(4): 473-85, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25865734
8.
CKD-Associated Pruritus and Clinical Outcomes in Nondialysis CKD.
Kidney Med
; 6(1): 100754, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38225976
9.
The Burden of Pruritus Associated With CKD: A Mixed Methods Analysis Among Patients Undergoing Dialysis.
Kidney Med
; 5(9): 100696, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37637864
10.
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.
Kidney Med
; 4(8): 100513, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36039153
11.
Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study.
Kidney Med
; 4(10): 100542, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36185706
12.
Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
Kidney Med
; 4(8): 100512, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36016762
13.
Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
J Patient Rep Outcomes
; 5(1): 134, 2021 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34952964
14.
Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients.
Kidney Med
; 3(1): 42-53.e1, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604539
15.
Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
Pain Physician
; 20(1): E183-E193, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28072811
16.
Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.
Clin Ther
; 38(2): 302-14, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26749219
17.
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.
Pain
; 157(9): 1851-1871, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27152687
18.
Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
Postgrad Med
; 127(1): 5-12, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25526227
19.
Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets.
J Opioid Manag
; 11(6): 519-33, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26728649
20.
12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
J Opioid Manag
; 11(4): 339-56, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26312961